Influx Healthtech Ltd
INFLUX NSE
Influx Healthtech Ltd
HealthcareNSE: INFLUX Pharmaceuticals
Key Fundamentals
SMEPharmaceuticalsHealthcareMarket Cap
₹695 Cr
Volatility
Moderate
P/E Ratio
34
EBITDA
₹29.86 Cr
Return on Equity
36.98%
Debt to Equity
0
Book Value
₹43.52
52W High
₹315
52W Low
₹160.6
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Influx Healthtech Ltd insights
41 extracted metrics + investor summaries across FY21–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
3- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 39.1%
Weaknesses
2- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 48.1 days to 83.5 days
Growth Rate
Revenue Growth
39.84% ↘
Net Income Growth
50.07% ↘
Cash Flow Change
-21.03% ↘
ROE
-24.30% ↘
ROCE
-25.01% ↘
EBITDA Margin (Avg.)
2.18% ↗
Quarterly Results
| Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 48 | 57 | 67 | 80 |
| Expenses | 39 | 45 | 52 | 65 |
| Operating Profit | 9 | 11 | 15 | 15 |
| OPM % | 19% | 20% | 22% | 19% |
| Other Income | 0 | 0 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 2 | 2 | 2 |
| PBT | 8 | 10 | 13 | 14 |
| Tax % | 27% | 24% | 23% | 25% |
| Net Profit | 6 | 8 | 10 | 11 |
| EPS in Rs | 3.1 | 4.21 | 4.32 | 4.56 |
Profit & Loss
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 0 | 59 | 76 | 100 | 105 | 147 |
| Expenses | 0 | 53 | 65 | 83 | 84 | 117 |
| Operating Profit | 0 | 6 | 11 | 17 | 21 | 30 |
| OPM % | — | 11% | 14% | 17% | 20% | 20% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 1 | 2 | 3 | 4 |
| PBT | 0 | 6 | 10 | 15 | 18 | 27 |
| Tax % | — | 26% | 26% | 25% | 25% | 25% |
| Net Profit | 0 | 4 | 7 | 11 | 13 | 21 |
| EPS in Rs | 0 | 1,800 | 2,880 | 4,452 | 7.37 | 8.87 |
| Div. Payout % | — | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.03 | 0.03 | 0.03 | 0.03 | 18 | 23 |
| Reserves | 0 | 4 | 12 | 23 | 18 | 78 |
| Borrowings | 0 | 1 | 1 | 0 | 0 | 0 |
| Other Liabilities | 0 | 12 | 16 | 18 | 34 | 23 |
| Total Liabilities | 0 | 18 | 28 | 41 | 70 | 124 |
| Fixed Assets | 0 | 3 | 6 | 14 | 19 | 28 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 2 |
| Other Assets | 0 | 15 | 22 | 27 | 52 | 90 |
| Total Assets | 0 | 18 | 28 | 41 | 70 | 124 |
Cash Flow
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Operating | 0 | 4 | 7 | 9 | 7 | 4 |
| Investing | 0 | -3 | -5 | -8 | -9 | -25 |
| Financing | 0 | 1 | 0 | -1 | 0 | 45 |
| Net Cash Flow | 0 | 1 | 2 | 0 | -2 | 23 |
| Free Cash Flow | 0 | 1 | 2 | 1 | -1 | -21 |
| CFO/OP | — | 89 | 87 | 70 | 56 | 41 |
Ratios
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | — | 64 | 66 | 58 | 113 | 84 |
| Inventory Days | — | 14 | 18 | 41 | 112 | 67 |
| Days Payable | — | 88 | 123 | 106 | 248 | 80 |
| Cash Conversion Cycle | — | -10 | -39 | -6 | -24 | 71 |
| Working Capital Days | — | 2 | 1 | 15 | 46 | 83 |
| ROCE % | — | 237% | 111% | 85% | 60% | 40% |
Documents
1
Copy of Newspaper Publication
25 Aug - Newspaper advertisements published for 6th AGM and e-voting instructions on August 25, 2026. 25 Aug - Newspaper advertisements published for 6th AGM and e-voting instructions on August 25, 2026.
2
Updates
10 Jul - Q1FY27 update: ₹10 Cr capacity expansion, 2.5x manufacturing uplift, FY27 revenue growth guided 25–30%. 10 Jul - Q1FY27 update: ₹10 Cr capacity expansion, 2.5x manufacturing uplift, FY27 revenue growth guided 25–30%.
3
Certificate under SEBI (Depositories and Participants) Regulations, 2018
10 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026. 10 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026.
4
Reply to Clarification- Financial results
3 Jul - Audited FY26 results filed; consolidated format clarified for newly incorporated subsidiary Olahey Wellness. 3 Jul - Audited FY26 results filed; consolidated format clarified for newly incorporated subsidiary Olahey Wellness.
5
Clarification - Financial Results
24 Jun - Exchange has sought clarification from Influx Healthtech Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On … 24 Jun - Exchange has sought clarification from Influx Healthtech Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On …
Frequently Asked Questions about Influx Healthtech Ltd
What does Influx Healthtech Ltd do?
Incorporated in 2020, Influx Healthtech Ltd is a CDMO which deals in nutraceuticals, Ready-to-Drink (RTD) beverages, functional nutrition and pet care.[1]
Where is Influx Healthtech Ltd (INFLUX) listed?
Influx Healthtech Ltd is listed on the Indian stock exchanges. It is listed on NSE: INFLUX. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Influx Healthtech Ltd belong to?
Influx Healthtech Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Influx Healthtech Ltd?
Influx Healthtech Ltd has a market capitalisation of approximately ₹694.51 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Influx Healthtech Ltd?
The Price-to-Earnings (PE) ratio of Influx Healthtech Ltd is 34.00. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Influx Healthtech Ltd?
Over the past 52 weeks, Influx Healthtech Ltd has traded between a low of ₹160.6 and a high of ₹315. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Influx Healthtech Ltd?
Influx Healthtech Ltd has a Return on Equity (ROE) of 36.98%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Influx Healthtech Ltd on Tapetide?
On Tapetide, you can view Influx Healthtech Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 2020, Influx Healthtech Ltd is a CDMO which deals in nutraceuticals, Ready-to-Drink (RTD) beverages, functional nutrition and pet care.[1]